Q32 Bio INC Form 4 insider transactions

Q32 Bio Inc. CEO Jodie Pope Morrison sold 22,506 shares of common stock for $3.46 per share under a Rule 10b5-1 plan.

Lee Kalowski, CFO and President of Q32 Bio Inc., reported the sale of 9,072 shares of common stock at $3.4607 per share, reducing his direct beneficial ownership to 39,938 shares.

Q32 Bio Inc. director Sven Ante Lundberg was granted 53,521 stock options with an exercise price of $2.8, vesting by October 2026.

Q32 Bio Inc. Director Mark T. Iwicki was granted 53,521 stock options with an exercise price of $2.80, vesting by October 23, 2026.

Q32 Bio Inc. Director Isaac Manke acquired 53,521 stock options with an exercise price of $2.80, vesting by October 2026.

Q32 Bio Inc. Director Diyong Xu acquired 53,521 stock options with an exercise price of $2.8, vesting by October 2026 or the next annual meeting.

Q32 Bio Inc. Director Mary Thistle acquired 53,521 stock options with an exercise price of $2.8, vesting by October 2026.

Q32 Bio Inc. director David S. Grayzel was granted 53,521 stock options with an exercise price of $2.8, vesting upon continued service.

Q32 Bio Inc. Director Arthur Tzianabos was granted 53,521 stock options with an exercise price of $2.80, vesting upon continued service.

Q32 Bio Inc. Director Kathleen Laporte was granted 53,521 stock options with an exercise price of $2.80, vesting by October 2026.

Q32 Bio Inc. CEO Jodie Pope Morrison sold 10,494 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Q32 Bio's Chief Scientific Officer, Shelia M. Violette, sold 2,990 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Q32 Bio Inc.'s CFO and President, Lee Kalowski, sold 4,240 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Director Isaac Manke reports option repricing and grant in Q32 Bio Inc. shares.

Lee Kalowski, CFO and President of Q32 Bio Inc., reports changes in beneficial ownership following an option repricing approved by the company's board of directors.

Kathleen Laporte, a director at Q32 Bio Inc., received repriced stock options on February 24, 2025, as approved by the company's board of directors.

Director Arthur Tzianabos received repriced stock options from Q32 Bio Inc. on February 24, 2025, according to a Form 4 filing.

CEO Jodie Pope Morrison reports changes in beneficial ownership of Q32 Bio Inc. stock and options following an option repricing approved by the board of directors.

Director Xu Diyong received an option repricing from Q32 Bio Inc. on February 24, 2025, affecting stock options exercisable for common stock.

Director Mark Iwicki reports adjustments to stock options in Q32 Bio Inc. following a board-approved repricing.

Q32 Bio Inc.'s Chief Medical Officer, Jason Campagna, received restricted stock units and had existing stock options repriced on February 24, 2025.

Director David S. Grayzel reports changes in beneficial ownership of Q32 Bio Inc. stock options, including repricing and new grants.

Mary Thistle, a director at Q32 Bio Inc., received an option repricing on February 24, 2025, affecting stock options exercisable for common stock.

Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc., reports the repricing of stock options and the grant of restricted stock units (RSUs) on February 24, 2025.

Director Sven Ante Lundberg reports repricing of stock options and grant of additional options in Q32 Bio Inc.

Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc., reports exercising stock options and subsequent changes in beneficial ownership of common stock.

Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc., exercised stock options and disposed of shares on October 8, 2024.

Director Isaac Manke of Q32 Bio Inc. receives stock options in lieu of cash compensation for serving as a non-employee director.

Director Sven Ante Lundberg acquired stock options in Q32 Bio Inc. on September 25, 2024.

Director David S. Grayzel acquired stock options in Q32 Bio Inc. in lieu of cash compensation, according to a Form 4 filing.